• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Bridgebio Pharma Inc (NQ: BBIO )

    25.62 +0.15 (+0.59%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Apr 30, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 1,589,035
    Open 25.22
    Bid (Size) 24.94 (20)
    Ask (Size) 25.75 (2)
    Prev. Close 25.47
    Today's Range 24.95 - 26.05
    52wk Range 13.00 - 44.32
    Shares Outstanding 160,500,999
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
    From BridgeBio Pharma, Inc.
    Via GlobeNewswire
    BridgeBio Pharma Presents Cardiac Magnetic Resonance (CMR) Imaging Evidence Consistent with Clinical Improvement Observed in the ATTRibute-CM Phase 3 Study in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
    From BridgeBio Pharma, Inc.
    Via GlobeNewswire

    Performance

    YTD
    -36.66%
    -36.66%
    1 Month
    -14.54%
    -14.54%
    3 Month
    -32.29%
    -32.29%
    6 Month
    +0.43%
    +0.43%
    1 Year
    +78.66%
    +78.66%

    More News

    Read More
    BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
    From BridgeBio Pharma, Inc.
    Via GlobeNewswire
    Recap: BridgeBio Pharma Q4 Earnings
    Via Benzinga
    BridgeBio Pharma Inc. (NASDAQ: BBIO) is a Stock Spotlight on 1/9
    Via Investor Brand Network
    BridgeBio Pharma Announces Pricing of Public Offering of Common Stock
    From BridgeBio Pharma, Inc.
    Via GlobeNewswire
    BridgeBio Pharma Announces Proposed Public Offering of Common Stock
    From BridgeBio Pharma, Inc.
    Via GlobeNewswire
    What's Going On With BridgeBio Pharma Stock On Monday?
    Via Benzinga
    Exposures Product Safety
    BridgeBio, A Top 3% Biotech, Just Snagged A $310 Million Deal; Will Shares Break Out?
    Via Investor's Business Daily
    2 Biotechs That Could Get Bought Out in 2024
    Via The Motley Fool
    BridgeBio Pharma and Bayer Announce European Licensing Agreement for Acoramidis in ATTR-CM
    From BridgeBio Pharma, Inc.
    Via GlobeNewswire
    BridgeBio Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Business Update
    From BridgeBio Pharma, Inc.
    Via GlobeNewswire
    Reliance Steel & Aluminum Posts Upbeat Earnings, Joins JFrog, AppLovin, Shake Shack And Other Big Stocks Moving Higher On Thursday
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    BridgeBio Pharma and Kyowa Kirin Announce Partnership with an Upfront Payment of $100 Million for an Exclusive License on Infigratinib in Skeletal Dysplasias in Japan
    From BridgeBio Pharma, Inc.
    Via GlobeNewswire
    BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
    From BridgeBio Pharma, Inc.
    Via GlobeNewswire
    BridgeBio Pharma Announces U.S. Food and Drug Administration (FDA) Acceptance of New Drug Application (NDA) for Acoramidis for the Treatment of Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
    From BridgeBio Pharma, Inc.
    Via GlobeNewswire
    BridgeBio Pharma Shares Positive Results of Single-Arm Phase 3 Study of Acoramidis in Japanese Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Including No Mortality Reported in the Trial at 30 Months
    From BridgeBio Pharma, Inc.
    Via GlobeNewswire
    3 Groundbreaking Biotech Stocks to Invest in Now
    Via InvestorPlace
    7 Exciting Stocks Poised for Explosive Growth in Key Sectors
    Via InvestorPlace
    BridgeBio Pharma Secures up to $1.25 Billion of Capital from Blue Owl and CPP Investments to Accelerate the Development and Launch of Genetic Medicines
    From BridgeBio Pharma, Inc.
    Via GlobeNewswire
    BridgeBio Pharma Announces Publication of Positive Results from Phase 3 ATTRibute-CM Study of Acoramidis for Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) in the New England Journal of Medicine
    From BridgeBio Pharma, Inc.
    Via GlobeNewswire
    BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
    From BridgeBio Pharma, Inc.
    Via GlobeNewswire
    BridgeBio Pharma to Participate in the J.P. Morgan Healthcare Conference
    From BridgeBio Pharma, Inc.
    Via GlobeNewswire
    BridgeBio announces FDA clearance of IND application for BBO-8520, a first-in-class direct inhibitor of KRASG12C (ON)
    From BridgeBio Pharma, Inc.
    Via GlobeNewswire
    3 Russell 2000 Stocks That Are About to Get Absolutely Crushed
    Via InvestorPlace
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.